BioCentury
ARTICLE | Company News

Pharmascience, GlaxoSmithKline deal

December 17, 2012 8:00 AM UTC

Pharmascience and Human Genome Sciences Inc. mutually terminated a 2007 deal granting Human Genome ex-Japanese rights to HGS1029 ( AEG40826). Pharmascience, which regains worldwide rights to the small molecule antagonist against inhibitor of apoptosis (IAP) proteins, said it is exploring development plans and partnering opportunities to advance the product. Pharmascience declined to disclose the reason for the termination, while GSK could not be reached for details. Human Genome had rights to the compound and related compounds from Aegera Therapeutics Inc., which Pharmascience acquired in May 2011(see BioCentury, Dec. 24, 2007 & June 6, 2011). ...